BRCA2 reversion mutation confers resistance to olaparib in breast cancer

BRCA2 reversion mutation confers resistance to olaparib in breast cancer

Key Clinical Message A rare missense mutation was identified as a reversion mutation using cancer genomic profiling and a suspected mechanism underlying resistance to olaparib in breast cancer. Abstract A 34‐year‐old woman with breast cancer and BRCA2: p.Gln3047Ter was treated with olaparib. After t...

Full description

Bibliographic Details
Main Authors: Shinya Yamamoto, Kei Kawashima, Yoshie Fujiwara, Shoko Adachi, Kazutaka Narui, Chiaki Hosaka, Rina Takahashi, Sho Tsuyuki, Makoto Sugimori, Miki Tanoshima, Mahato Sasamoto, Masanori Oshi, Akimitsu Yamada, Chikara Kunisaki, Itaru Endo
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Clinical Case Reports
Subjects:
BRCA
breast neoplasms
genomics
olaparib
Online Access:https://doi.org/10.1002/ccr3.7537

Internet

https://doi.org/10.1002/ccr3.7537

Similar Items